Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 8/20 | 0.46 |
| ▸ | TSHR | P16473 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | NAMPT | P43490 | 1/20 | 0.37 |
| ▸ | FAAH | O00519 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.35 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.35 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13699563 | 0.95 | GLP1R (0.47) | GLP1RTSHRALDH1A1NAMPTFAAH | |
| SCHEMBL3485672 | 0.88 | GLP1R (0.56) | GLP1RTSHRSIRT2SIRT1 | |
| SCHEMBL3485679 | 0.88 | GLP1R (0.56) | GLP1RTSHRSIRT2SIRT1 | |
| SCHEMBL13699566 | 0.86 | GLP1R (0.58) | GLP1RTSHRALDH1A1EPHX2SIRT1 | |
| SCHEMBL16076995 | 0.86 | GLP1R (0.58) | GLP1RTSHRMAPTHSD17B10SIRT1 | |
| SCHEMBL3485126 | 0.85 | GLP1R (0.45) | GLP1RTSHRFAAHMAPTHSD17B10 | |
| SCHEMBL3485131 | 0.85 | GLP1R (0.45) | GLP1RTSHRFAAHMAPTHSD17B10 | |
| SCHEMBL22096266 | 0.85 | GLP1R (0.46) | GLP1RTSHRNAMPTFAAHEPHX2 | |
| SCHEMBL25585043 | 0.85 | GLP1R (0.46) | GLP1RTSHRNAMPTFAAHEPHX2 | |
| SCHEMBL11925975 | 0.85 | GLP1R (0.53) | GLP1RTSHRFAAHEPHX2SIRT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090240028-A1 | Synthesis and Application of New Structural Well Defined Branched Polymers as Conjugating Agents for Peptides | NOVO NORDISK A/S (DK) | 2009-09-24 | — | — | US | disclosed |
| US-20090240028-A1 | Synthesis and Application of New Structural Well Defined Branched Polymers as Conjugating Agents for Peptides | NOVO NORDISK A/S (DK) | 2009-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090240028-A1 | Synthesis and Application of New Structural Well Defined Branched Polymers as Conjugating Agents for Peptides | VIP, PTMS, PDGFA | GLP1R 103/4885TSHR 1791/4885ALDH1A1 4789/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.